Toni Choueiri, Dana-Farber Cancer Institute (IMAGE)

Dana-Farber Cancer Institute

Toni Choueiri, Dana-Farber Cancer Institute

Caption

An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial by researchers at Dana-Farber Cancer Institute.

Credit

Dana-Farber Cancer Institute

Usage Restrictions

None

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.